Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-23 02:24 CEST (UTC+2h)

Replicate vs. 2×2×2 (ethics?) [Regulatives / Guidelines]

posted by nobody - 2017-05-08 14:52  - Posting: # 17317
Views: 7,882

» » … and not as a result of outliers
» Nobody knows how to deal with this story. :-( Regulations  science. Not required by the FDA…

... sorry, no.

But this "it's safe because it has been shown to be safe in clinical practice over the last decades"-argumentation (question one above) never really went well in EU, I guess. At least you need to write a new, Chapter 2.5-like overview on the pk, pharmacology, safety to make the assessor sleep well next night after reading your application for a generic. On the other hand, assessors for originator's MAs have a much, much better sleep (better sleeping pills?), in my experience...

Edit: Please don’t shout! [Helmut]

Kindest regards, nobody

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,190 registered users;
online 12 (0 registered, 12 guests [including 11 identified bots]).

[The] impatience with ambiguity can be criticized in the phrase:
absence of evidence is not evidence of absence.    Carl Sagan

BEBAC Ing. Helmut Schütz